Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.
Medscape1d
Are GLP-1s the Newest Fertility Treatment?
Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...
HealthDay on MSN4d
Medicaid covers GLP-1 weight-loss drugs in just 13 states
Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...
4 Ways to Prevent Muscle Loss on Ozempic & Other Weight Loss GLP-1 Medications
You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...
UPI4d
Medicaid covers GLP-1 weight-loss drugs in just 13 states
Related Ozempic, Wegovy might help ease knee arthritis pain Weight-loss surgeries decline 25% as GLP-1 drugs grow in popularity Ozempic, Wegovy might lower Alzheimer's risk in Type 2 diabetics But ...
AOL5d
4 Ways to Prevent Muscle Loss on Ozempic & Other Weight Loss GLP-1 Medications
You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists like Ozempic®, Wegovy®, Mounjaro®, and Zepbound®. While Ozempic can ...
Axios Vitals on MSN4d
States slow to cover GLP-1s for weight loss
Axios Visuals Budget pressures have kept all but 13 states from covering GLP-1 drugs for weight loss through their Medicaid programs, a new report from KFF shows. Why it matters: The restrictive ...
Yahoo Finance4d
Hanmi Unveils Novel Obesity Drug 'HM17321' : A Game-Changer in Overcoming GLP-1-Associated Muscle Loss
HM17321 addresses a key limitation in current GLP-1-based therapies, which often lead to muscle loss as a side effect of significant weight reduction. "HM17321 is the novel concept of obesity drug ...